Analyst Yun Zhong from Wedbush maintained a Hold rating on Keros Therapeutics (KROS – Research Report) and keeping the price target at $15.00.
Yun Zhong has given his Hold rating due to a combination of factors surrounding Keros Therapeutics. The recent Phase 1 data for KER-065 showed promising results in terms of biomarker changes related to bone turnover, fat mobilization, and muscle mass increase. However, the dose-dependent increase in hemoglobin levels raises concerns about the safety profile, creating uncertainties that need to be addressed before moving forward.
Furthermore, while KER-065 presents a unique approach for treating Duchenne muscular dystrophy (DMD), many details of the Phase 2 study are still pending finalization. The company’s financial position is strong, with significant cash reserves and a partnership with Takeda, but the strategic use of these resources remains a key focus for investors. Given these mixed signals, Zhong maintains a Neutral rating with a price target of $15, reflecting both the potential and the risks associated with KER-065’s development.